Healthcare Jan 06, 2022 11:27 AM (GMT+8) · EqualOcean
On January 5, the website of the drug evaluation center (CDE) of the State Food and Drug Administration of China showed that Hengrui medicine had submitted the new drug listing application of shr8008 capsule. Shr8008 is a new antifungal drug introduced by Hengrui pharmaceutical from mycovia pharmaceuticals with more than US $100 million. According to the press release released by Hengrui medicine earlier, the indication of shr8008 capsule for this application is acute vulvovaginal candidiasis. Shr8008 (oteseconazole) is a new oral azole antifungal drug developed by mycovia company, which can highly specifically inhibit fungal CYP51 enzyme. According to the press release released by mycovia earlier, the design of shr8008 makes it more selective, less side effects and better efficacy than the currently available antifungal drugs. In June 2019, the company has worked with Mycovia to obtain exclusive rights in the Greater China region (Chinese mainland, Hongkong, Macao and Taiwan). The SHR8008 has been developed and commercialized for the treatment or prevention of a series of fungal diseases, including recurrent vulvovaginal candidiasis, onychomycosis and invasive fungal infections.

This text is a result of machine translation.

Related companies：